Galecto, Inc. (GLTO)
NASDAQ: GLTO · IEX Real-Time Price · USD
0.556
-0.021 (-3.57%)
At close: Jul 19, 2024, 4:00 PM
0.550
-0.006 (-1.08%)
Pre-market: Jul 22, 2024, 8:00 AM EDT
Galecto Employees
Galecto had 13 employees as of December 31, 2023. The number of employees decreased by 32 or -71.11% compared to the previous year.
Employees
13
Change (1Y)
-32
Growth (1Y)
-71.11%
Revenue / Employee
n/a
Profits / Employee
-$2,371,692
Market Cap
15.07M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 13 | -32 | -71.11% |
Dec 31, 2022 | 45 | 5 | 12.50% |
Dec 31, 2021 | 40 | 12 | 42.86% |
Dec 31, 2020 | 28 | - | - |
Related Stocks
Company Name | Employees |
---|---|
China Jo-Jo Drugstores | 938 |
Centogene | 384 |
BIMI International Medical | 296 |
Star Equity Holdings | 171 |
Talis Biomedical | 99 |
Evaxion Biotech | 49 |
Chemomab Therapeutics | 20 |
Edesa Biotech | 16 |
GLTO News
- 2 months ago - Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab - GlobeNewsWire
- 7 months ago - Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis - GlobeNewsWire
- 9 months ago - Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial - GlobeNewsWire
- 10 months ago - Galecto Announces Plans to Explore Strategic Alternatives - GlobeNewsWire
- 11 months ago - Galecto to Present at Investor Conferences in September - GlobeNewsWire
- 1 year ago - Galecto shares drop 65% as biotech halts development of lung-disease treatment - Market Watch
- 1 year ago - Galecto to discontinue development of lung disease treatment - Reuters
- 1 year ago - Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis - GlobeNewsWire